Login
Request Demo
Publications

Are high coronary risk patients missing out on lipid-lowering drugs in Australia?

This study examined whether high coronary risk patients in Australia, where use of lipid-lowering drugs (LLD) is very high by international standards, are receiving LLD.

Authors: Leon A Simons and Eric Chung

Medical Journal Australia 2014; 201: 213-216

Download document

Download Now
high coronary riskHypercholersterolemiahypertensionlipid-lowering drugs

Related Resources

Real-world study of the use of azacitidine in myelodysplasia in Australia

Uncovering real-world insights into MDS treatment in Australia: Our study in eJHaem highlights the importance of treatment adherence and the need for innovative solutions.

Real-World Study: Treatment Persistence in Pulmonary Arterial Hypertension Patients

The study analysed real-world data to compare treatment persistence and adherence among PAH patients on ERAs in Japan. Results showed significantly higher persistence with a medication compared to the other two medications.

Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia

This study aimed to examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.

Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions

Gout is the most common form of inflammatory arthritis in men. Despite the availability of effective urate-lowering therapies (ULT), the management of gout is suboptimal due to poor persistence with ULT. This study examined national prescribing patterns of ULT to...